Skip to main content

Harvard Bioscience, Inc.

corporate_fare Company Profile

Harvard Bioscience, Inc.

HBIO·NASDAQ·Industrial Applications And Services·CIK 0001123494

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing for pharmaceutical and therapy development. The company sells its products and services globally to academic institutions, government laboratories, and pharmaceutical, biotechnology, and contract research organizations (CROs). Harvard Bioscience operates in the United States, Europe, and China, utilizing both direct and distribution channels to reach customers worldwide. The business began in 1901 as Harvard Apparatus, founded by Dr. William T. Porter. Early inventions included ventilators based on Dr. Porter's design, the mechanical syringe pump in the 1950s, and the microprocessor-controlled syringe pump in the 1980s. Harvard Bioscience, Inc. was incorporated in Delaware in September 2000 and became the successor to Harvard Apparatus, Inc. in November 2000. In 2018, the company acquired Data Sciences International, Inc. (DSI), a global leader in products, services, and solutions for preclinical testing. The DSI product portfolio complements Harvard Bioscience's cellular and molecular technology (CMT) product portfolio, expanding its offerings from research and discovery to preclinical testing, with primary applications in drug and therapy testing.

Harvard Bioscience, Inc. (NASDAQ:HBIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 28 items for HBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for HBIO spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Harvard Bioscience 10-Q: Q3 Loss Widens to $2.6M, Cash Falls to $4.9M With Going-Concern Review
  • Harvard Bioscience Cuts FY26 Adjusted EBITDA Guidance to (1%)-4% From 6%-10%
  • Harvard Bioscience Q3 Revenue Up 8% to $22.2M; Full-Year EBITDA Guidance Cut
  • Harvard Bioscience Posts $0.58 Per-Share Q3 Loss
  • Harvard Bioscience Lifts Full-Year Outlook as Q2 Revenue Climbs 11%

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$86.55M
Net Income
-$56.7M
Diluted EPS
-$1.28
Op. Cash Flow
$6.73M
Free Cash Flow
$5.47M
Gross Profit
$49.91M
Operating Income
-$48.58M
Cash & Equivalents
$8.61M
Total Debt
$35.87M
Debt / Equity
2.61×
Net Margin
-65.5%
Shares Outstanding
44.72M sh
Source: 10-K · filed 2026-03-13 · accession 0001171843-26-001548

Short Interest & Short Volume

3.50 days to cover

FINRA reported short interest of 66,461 shares in HBIO as of the October 30, 2026 settlement, a 32.5% increase from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 34.3% of HBIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)66,461 shares as of October 30, 2026
Change vs prior period▲ 32.5%
Days to cover3.50 at avg daily volume of 19,000
Daily short volume (FINRA facilities)34.3% of 12,776 shares on November 20, 2026
5-day average short volume21.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with H →
$8.49 -1.96% today
52-week range · as of 2026-11-10 $4 – $9.6
Market cap
$39.6M
Volume
22.7K (0.9× avg)
3-mo avg 26K
Live data · 2026-11-21 21:03 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HBIO - Latest Insights

HBIO
Nov 10, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.26
Real-time Price: $8.49 info
Change: -$0.770 (-8%) info
Market Cap: $39.603M info
HBIO
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.09
Real-time Price: $8.49 info
Change: -$0.600 (-7%) info
Market Cap: $39.603M info
HBIO
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.09
Real-time Price: $8.49 info
Change: -$0.600 (-7%) info
Market Cap: $39.603M info
HBIO
Nov 10, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $9.09
Real-time Price: $8.49 info
Change: -$0.600 (-7%) info
Market Cap: $39.603M info
HBIO
Aug 11, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.13
Real-time Price: $8.49 info
Change: +$2.36 (+38%) info
Market Cap: $39.603M info
HBIO
Aug 11, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.41
Real-time Price: $8.49 info
Change: +$2.08 (+32%) info
Market Cap: $39.603M info
HBIO
Jun 02, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.46
Real-time Price: $8.49 info
Change: +$2.03 (+31%) info
Market Cap: $39.603M info
HBIO
May 12, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.41
Real-time Price: $8.49 info
Change: +$3.08 (+57%) info
Market Cap: $39.603M info
HBIO
May 12, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.78
Real-time Price: $8.49 info
Change: +$1.71 (+25%) info
Market Cap: $39.603M info
HBIO
Apr 21, 2026, 4:58 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $6.56
Real-time Price: $8.49 info
Change: +$1.93 (+29%) info
Market Cap: $39.603M info
HBIO
Apr 21, 2026, 4:56 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $6.56
Real-time Price: $8.49 info
Change: +$1.93 (+29%) info
Market Cap: $39.603M info
HBIO
Apr 01, 2026, 9:44 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $5.00
Real-time Price: $8.49 info
Change: +$3.49 (+70%) info
Market Cap: $39.603M info
HBIO
Mar 23, 2026, 8:00 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $5.26
Real-time Price: $8.49 info
Change: +$3.23 (+61%) info
Market Cap: $39.603M info
HBIO
Mar 18, 2026, 2:13 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $4.77
Real-time Price: $8.49 info
Change: +$3.72 (+78%) info
Market Cap: $39.603M info
HBIO
Mar 18, 2026, 7:31 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $5.10
Real-time Price: $8.49 info
Change: +$3.39 (+66%) info
Market Cap: $39.603M info
HBIO
Mar 17, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.14
Real-time Price: $8.49 info
Change: +$3.35 (+65%) info
Market Cap: $39.603M info
HBIO
Mar 13, 2026, 8:20 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.481
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Mar 12, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.4987
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Mar 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.4987
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Mar 10, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.486
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets